- Home
- INR vs CMPX Comparison
INR vs CMPX Comparison
Compare INR & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INR
- CMPX
- Stock Information
- Founded
- INR 2017
- CMPX 2014
- Country
- INR United States
- CMPX United States
- Employees
- INR N/A
- CMPX N/A
- Industry
- INR
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- INR
- CMPX Health Care
- Exchange
- INR NYSE
- CMPX Nasdaq
- Market Cap
- INR 295.3M
- CMPX 291.8M
- IPO Year
- INR 2025
- CMPX N/A
- Fundamental
- Price
- INR $15.37
- CMPX $2.65
- Analyst Decision
- INR Strong Buy
- CMPX Strong Buy
- Analyst Count
- INR 7
- CMPX 9
- Target Price
- INR $26.86
- CMPX $12.67
- AVG Volume (30 Days)
- INR 431.7K
- CMPX 797.6K
- Earning Date
- INR 08-11-2025
- CMPX 08-11-2025
- Dividend Yield
- INR N/A
- CMPX N/A
- EPS Growth
- INR N/A
- CMPX N/A
- EPS
- INR 1.89
- CMPX N/A
- Revenue
- INR $293,962,000.00
- CMPX $850,000.00
- Revenue This Year
- INR $49.00
- CMPX N/A
- Revenue Next Year
- INR $16.39
- CMPX N/A
- P/E Ratio
- INR $8.08
- CMPX N/A
- Revenue Growth
- INR 62.18
- CMPX N/A
- 52 Week Low
- INR $13.64
- CMPX $0.87
- 52 Week High
- INR $23.00
- CMPX $4.08
- Technical
- Relative Strength Index (RSI)
- INR N/A
- CMPX 64.52
- Support Level
- INR N/A
- CMPX $2.62
- Resistance Level
- INR N/A
- CMPX $2.87
- Average True Range (ATR)
- INR 0.00
- CMPX 0.16
- MACD
- INR 0.00
- CMPX 0.00
- Stochastic Oscillator
- INR 0.00
- CMPX 81.03
About INR INFINITY NATURAL RESOURCES INC
Infinity Natural Resources Inc is an oil and natural gas exploration and production company. The group focused on developing unconventional reserves in Appalachia. The company is engaged in acquiring, exploring, producing, and developing properties for producing oil, natural gas, and natural gas liquids (NGLs) from underground reservoirs.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.